5-MeO-DMT

Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates

Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development

GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates

Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development

GH Research: Steady Expenses And $229M Cash Position For 2026 Runway

GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

5-MeO-DMT Recent News

GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second quarter en

Harnessing The Power Of 5-MeO-DMT For Women Trauma Survivors: A Specialized Retreat

The following is Part II of our Tandava coverage. For Part I, click here.

All On Board For 5-MeO-DMT: This Retreat Hosts Expertly Guided Experiences For Women, BIPOC

The following is Part I of our Tandava coverage. For Part II, click here.

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023.

Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression

Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound

UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage

Clinical-stage private biotech company Beckley Psytech Ltd has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment.

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products

Two psychedelics companies have shared their updates and key milestones to be reached this 2023.

New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer's

Psychedelics R&D biotech Biomind Labs Inc.

Phase 2 Trial For This Psychedelic, Potential Treatment For Severe Depression

Private clinical-stage psychedelics biotech Beckley Psytech Ltd. has initiated a Phase 2a proof-of-concept study on BPL-003, its proprietary intranasal formulation of synthetic 5-MeO-DMT for Treatment-Resistant Depression (TRD.)

Psychedelic Experiences: UCL Leads First-Ever Brain Imaging Study In Retreat Participants

Public psychedelics practitioner training program F.I.V.E. is set to collaborate with Tandava Retreats and University College London (UCL) on what will be the first-ever EEG brain imaging study of 5-MeO-DMT done in retreat center participants.

Beyond Magic Mushrooms: Positive Clinical Trial For Treatment-Resistant Depression & Alcoholism

Private clinical-stage psychedelics biotech Beckley Psytech announced it has successfully completed a Phase 1 clinical study on BPL-003, its patent-protected, synthetic intranasal formulation of 5-MeO-DMT un

Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders

Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing.

Can Psychedelics Alleviate Prolonged Grief? Austin's Dell Med School Launches Clinical Trial To Find Out

Researchers at the University of Texas (UT) Dell Medical School in Austin will use brain scans to examine responses following treatment with psilocybin and 5-MeO-DMT for combatants suffering from post-traumatic stress disorder (PTSD), traumatic brain injuries and other related conditions.

Canadian Psychedelics Firm And Queens College Develop New Transdermal Drug Delivery System

Life and sciences R&D company Biomind Labs Inc.

Clinical Study On DMT Inhaled Product For Treatment-Resistant Depression Completes Dosing Stage

Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.

DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results

PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, and mushroom producer Red Light Holland Corp. (OTC Pink: TRUFF) announced the

GH Research Shares Q2 2022 Financial Results & Business Updates

GH Research PLC (NASDAQ: GHRS), the clinical-stage biopharma company dedicated to transforming the treatment of psychiatric and neurological disorders through 5-MeO-DMT production, provided a financial and business update for the quarter ended June 30, 2022.

Inside A 5-MeO-DMT Retreat: Who Should And Shouldn't Embark On This 'Hero's Journey'

This article was originally published on Psychedelic Spotlight and appears here with permission.

Psychedelic Toads Pushed To The Limit, Conservationists Urge Synthetic 5-MeO-DMT Option

You can add the Sonoran Desert Toad to the current escalating body count of threatened species worldwide, as the amphibious creature’s psychoactive secretions continue to gain popularity with psychedelic enthusiasts.

5 Psychedelics For Mental Health

This article was originally published on The Bluntness and appears here with permission.

Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT

Beckley Psytech, a private company in the psychedelics space, announced that it has begun training psychotherapists for a Phase 2 clinical trial with 5-MeO-DMT, a strong and fast-acting psychedeli

A Deeper Look At DMT, The 'Spirit Molecule'

This article was originally published on Microdose and appears here with permission.

Psychedelic Medicine: 5-MeO-DMT Formula For Treatment-Resistant Depression Has Positive Trial Results

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffering from treatment-resistant depression (TRD).